Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 225 member B (FAM225B) is a long non-coding RNA (lncRNA) and does not code for a protein. It has been identified as a novel oncogenic lncRNA, often upregulated in various cancers such as nasopharyngeal carcinoma and glioblastoma. FAM225B acts primarily as a competing endogenous RNA (ceRNA), regulating gene expression post-transcriptionally by sponging specific microRNAs (notably miR-613, miR-1-3p, miR-206, and miR-205-5p), thereby increasing the expression of oncogenic proteins such as cyclin D2 (CCND2). High expression of FAM225B correlates with higher tumor grade, advanced clinical stage, metastasis, and poor overall survival. Functional studies show that reducing FAM225B expression impairs tumor cell proliferation, migration, and invasion both in vitro and in vivo, supporting its role as a potential prognostic biomarker and its mechanistic involvement in cancer progression[1][2]. There are currently no known drug interactions or direct targeting agents for FAM225B.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 225 member B (non-protein coding) (FAM225B).